caffeine citrate has been researched along with Bronchopulmonary Dysplasia in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 8 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, PY; Dong, QY; He, XR; Hu, JT; Li, W; Wang, T; Zhang, XF | 1 |
| Johnson, PN; Lim, SY; May, CB; Miller, JL | 1 |
| Brattström, P; Bruschettini, M; Davis, PG; Onland, W; Russo, C; Soll, R | 1 |
| Grunau, RE; Synnes, A | 1 |
| Cheong, JLY; Doyle, LW | 1 |
| Jensen, EA | 1 |
| Patel, RM; Saroha, V | 1 |
| Chen, X; Cheng, R; Feng, Y; Mao, XN; Qiu, J; Zhao, L | 1 |
| Gao, Z; Han, D; Kou, C; Li, Z; Liu, Z; Wu, W; Zhang, Y | 1 |
| Bendel-Stenzel, E; Chhabra, R; Harper, B; Ku, L; Laughon, M; Moya, F; Payne, EH; Puia-Dumitrescu, M; Smith, PB; Soriano, A; Wade, KC; Zhao, J | 1 |
| Chung, S; Chung, SH; Kim, KS; Kim, SN; Lim, G; Park, HW | 1 |
| Carnielli, VP; Fabbri, L; Ferrari, F; Kiechl-Kohlendorfer, U; Lasagna, G; Lista, G; Papagaroufalis, K; Polackova, R; Saenz, P | 1 |
| Bohlin, K; Jonsson, B; Kamper, J; Lindwall, R; Verder, H | 1 |
| El Ayoubi, M; Lescure, S; Lopez, E; Moriette, G | 1 |
| Duman, N; Kumral, A; Ozkan, H; Tuzun, F; Yesilirmak, DC | 1 |
| Catland, D; Coalson, JJ; Martin, H; Siler-Khodr, TM; Thomson, MA; Winter, VT; Yoder, BA | 1 |
7 review(s) available for caffeine citrate and Bronchopulmonary Dysplasia
| Article | Year |
|---|---|
Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Child; Humans; Infant; Infant, Extremely Premature; Infant, Newborn; Infant, Premature, Diseases | 2023 |
Neurodevelopmental outcomes after neonatal caffeine therapy.
Topics: Animals; Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Citrates; Developmental Disabilities; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Neurodevelopmental Disorders | 2020 |
What is bronchopulmonary dysplasia and does caffeine prevent it?
Topics: Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response Relationship, Drug; Female; Humans; Infant; Infant, Newborn; Infant, Very Low Birth Weight; Pregnancy; Premature Birth | 2020 |
Caffeine for preterm infants: Fixed standard dose, adjustments for age or high dose?
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Cerebral Hemorrhage; Citrates; Dose-Response Relationship, Drug; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Infant, Premature, Diseases | 2020 |
Early Caffeine Use in Very Low Birth Weight Infants and Neonatal Outcomes: A Systematic Review and Meta-Analysis.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Citrates; Enterocolitis, Necrotizing; Humans; Infant; Infant Mortality; Infant, Newborn; Infant, Very Low Birth Weight; Risk Factors; Treatment Outcome | 2015 |
Nasal CPAP and surfactant for treatment of respiratory distress syndrome and prevention of bronchopulmonary dysplasia.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Citrates; Combined Modality Therapy; Continuous Positive Airway Pressure; Humans; Infant, Newborn; Positive-Pressure Respiration; Pulmonary Surfactants; Respiration, Artificial; Respiratory Distress Syndrome, Newborn | 2009 |
[Apnea of prematurity: what's new?].
Topics: Apnea; Bradycardia; Brain Damage, Chronic; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Citrates; Combined Modality Therapy; Continuous Positive Airway Pressure; Gestational Age; Humans; Infant, Newborn; Infant, Premature, Diseases; Neonatal Screening; Oxygen; Risk Factors | 2010 |
2 trial(s) available for caffeine citrate and Bronchopulmonary Dysplasia
| Article | Year |
|---|---|
Influence of prevention of caffeine citrate on cytokine profile and bronchopulmonary dysplasia in preterm infants with apnea.
Topics: Apnea; Birth Weight; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Citrates; Drug Administration Schedule; Female; Gestational Age; Humans; Infant, Newborn; Infant, Premature; Infant, Very Low Birth Weight; Infusions, Intravenous; Interleukin-6; Interleukin-8; Length of Stay; Maintenance Chemotherapy; Male; Respiration, Artificial; Time Factors | 2020 |
Genetic basis of apnoea of prematurity and caffeine treatment response: role of adenosine receptor polymorphisms: genetic basis of apnoea of prematurity.
Topics: Bronchopulmonary Dysplasia; Caffeine; Case-Control Studies; Citrates; Drug Administration Schedule; Genetic Markers; Genotype; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Logistic Models; Polymorphism, Single Nucleotide; Prospective Studies; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A1; Receptors, Adenosine A2; Sleep Apnea Syndromes; Treatment Outcome | 2012 |
7 other study(ies) available for caffeine citrate and Bronchopulmonary Dysplasia
| Article | Year |
|---|---|
The timing of withdrawal from caffeine citrate in very preterm infants.
Topics: Bronchopulmonary Dysplasia; Caffeine; Citrates; Humans; Infant; Infant, Newborn; Infant, Premature; Retrospective Studies | 2021 |
Caffeine dosing in premature neonates: impact of birth weight on a pharmacokinetic simulation study.
Topics: Birth Weight; Bronchopulmonary Dysplasia; Caffeine; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature | 2023 |
Childhood respiratory outcomes after neonatal caffeine therapy.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Child; Citrates; Ductus Arteriosus, Patent; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Oxygen Inhalation Therapy | 2020 |
[Clinical effect of early or late administration of caffeine citrate in prevention and treatment of apnea in very low birth weight infants].
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Child; Citrates; Humans; Infant; Infant, Very Low Birth Weight; Retrospective Studies | 2018 |
Dosing and Safety of Off-label Use of Caffeine Citrate in Premature Infants.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Cerebral Hemorrhage; Citrates; Ductus Arteriosus, Patent; Electronic Health Records; Enterocolitis, Necrotizing; Female; Gestational Age; Humans; Infant, Extremely Premature; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Intensive Care Units, Neonatal; Intensive Care, Neonatal; Male; Multivariate Analysis; Off-Label Use; Treatment Outcome | 2019 |
The Real-World Routine Use of Caffeine Citrate in Preterm Infants: A European Postauthorization Safety Study.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Citrates; Europe; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Male; Product Surveillance, Postmarketing | 2016 |
Treatment of immature baboons for 28 days with early nasal continuous positive airway pressure.
Topics: Age Factors; Animals; Animals, Newborn; Biological Products; Biopsy; Bronchoalveolar Lavage Fluid; Bronchopulmonary Dysplasia; Caffeine; Cesarean Section; Citrates; Combined Modality Therapy; Continuous Positive Airway Pressure; Disease Models, Animal; Drug Combinations; Feasibility Studies; Humans; Infant, Newborn; Intensive Care, Neonatal; Lung; Papio; Parenteral Nutrition, Total; Phospholipids; Pulmonary Gas Exchange; Risk Factors; Time Factors; Ventilator Weaning | 2004 |